Lexeo Therapeutics, Inc. Common Stock
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $270.9M
- Price
- $3.30
- % Change (Daily % change from the live per-ticker quote feed.)
- -3.23%
- Volume
- 1.5M
About
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Quick stats
Shares outstanding82.1M
Computed float73.2M
Float / shares89.1%
Cash runway (months)29.1
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001907108
Websitehttps://www.lexeotx.com
AI Summary
AI-generated1/17
minorbullishclinical trial
Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)
Lexeo Therapeutics' abstract for LX2006, its AAV-based gene therapy for Friedreich ataxia, was accepted for an oral presentation at the MDS 2026 congress in Seoul on October 7.
The presentation will highlight previously reported early stabilization or improvement in mFARS scores versus a propensity-matched natural history control cohort, plus new mFARS subscore analyses.
LX2006 is in a Phase 2 registrational trial (SUNRISE-FA 2) and holds FDA Breakthrough Therapy and multiple other designations; the congress slot adds visibility but no new efficacy readout.